New regulatory decisions, manufacturing partnerships, and financing pressures are reshaping access, supply, and development pathways for emerging advanced therapies.
|Articles|February 1, 2015
- BioPharm International-02-01-2015
- Volume 28
- Issue 2
Colony Counter Increases Accuracy
Protos 3 is Synbiosis’ automated colony counter and chromogenic identification system.
Advertisement
Synbiosis’ automated colony counter and chromogenic identification system, Protos 3, is designed for walk-away colony counts in seconds and identifying microbial species by their color on chromogenic plates. The counter features a CCD camera with unique three-color LED lighting, which rapidly images an infinite number of colony colors on one plate and detects colonies as small as 0.043 mm.
The counter’s GLP-compliant software creates accurate counts and plate images and completes a full audit trail to eliminate errors.
Synbiosis
Articles in this issue
over 11 years ago
Finding Opportunities in Brazilover 11 years ago
Behind the Scenes with Buffersover 11 years ago
Peristaltic Pump Ensures Repeatabilityover 11 years ago
Tackling Analytical Method Development for ADCsover 11 years ago
Cures Require Compromiseover 11 years ago
Mitigating Risk for Single-Use Assemblies in Sterile Fillingover 11 years ago
FDA Sets Policies to Enhance Drug Security and Safetyover 11 years ago
Gauging the CMO Biosimilar Opportunityover 11 years ago
The Bullish Outlook for Biosimilarsover 11 years ago
Equivalence Testing for ComparabilityAdvertisement
Related to this article
Caribou is halting vispa-cel and CB-011, allogeneic CAR-T therapies that showed up to 92% response rates, citing a difficult financing environment.
Celltrion USA's Omlyclo, the first interchangeable biosimilar to Xolair, reaches the U.S. market across four allergic and inflammatory indications.
Alvotech turns to a CDMO's 40,000-liter Syracuse facility for biosimilar drug substance as it expands its manufacturing network.
AbbVie's c-Met ADC Temab-A showed a 15.6% response rate in late-line colorectal cancer ahead of its 2 new FDA breakthrough designations.
New data and partnerships are advancing brain-penetrant enzyme therapy, targeted antibodies, flexible obesity dosing, and frontline lymphoma treatment strategies.
Topline phase 3 data show epcoritamab plus R-CHOP reduced the risk of progression or death by 51% in newly diagnosed diffuse large B-cell lymphoma.
Part 2 of the VK2735 maintenance study tests whether daily or weekly oral tablets can hold weight loss first achieved with weekly subcutaneous injections.
Advertisement
Advertisement